力生制药：磷酸腺嘌呤原料药通过上市申请

Core Viewpoint - The company, Lifesun Pharmaceutical, has received approval from the National Medical Products Administration for the listing application of adenine phosphate raw material, which is expected to enhance its market competitiveness and create synergy with its formulation products [1] Group 1: Company Announcement - Lifesun Pharmaceutical announced the receipt of the approval notice for the listing application of adenine phosphate raw material from the National Medical Products Administration [1] - Adenine phosphate is a component of nucleic acids and coenzymes, involved in the synthesis of DNA and RNA in the body, and is clinically used to prevent and treat leukopenia caused by various reasons [1] Group 2: Market Implications - The approval of adenine phosphate raw material is expected to facilitate industrial synergy with the company's formulation products, thereby enhancing market competitiveness [1]